Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: TMS-for-depression pioneer Neuronetics readies for commercial ramp-up

This article was originally published in Clinica

Executive Summary

Being first to market is not always what it’s cracked up to be, especially when your product is an innovative technology. Not only do you have to get the first adopters on board, there is also the issue of securing reimbursement to spur uptake of your product. The latter is particularly challenging when there is no existing code for your innovation and you need to create your own reimbursable market.


Related Content

Neuronetics Launches Major Registry To Track NeuroStar TMS Outcomes





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts